title: Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Shin-Yeu
authors.initials: SY
authors.lastname: Ong
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore, Singapore.
authors.forename: Hong Yen
authors.initials: HY
authors.lastname: Ng
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Surendran
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Yeh Ching
authors.initials: YC
authors.lastname: Linn
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: YunXin
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Yeow Tee
authors.initials: YT
authors.lastname: Goh
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Colin
authors.initials: C
authors.lastname: Diong
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore. sathish.gopalakrishnan@sgh.com.sg.
authors.forename: Sathish Kumar
authors.initials: SK
authors.lastname: Gopalakrishnan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*
keywords: bortezomib; bortezomib-cyclophosphamide-dexamethasone; bortezomib-thalidomide-dexamethasone; cyclophosphamide; multiple myeloma; thalidomide